RxDoctor Payments Data

Angela Rodiek

Family · Anderson, SCNPI 1265073209

Payments from drug & device makers

$2,387in general payments, 2019–2025

Across 127 payments — averaging $18.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$515
  • AbbVie$395
  • Otsuka America Pharmaceutical, Inc.$267
  • Axsome Therapeutics, Inc.$239
  • Almatica Pharma LLC$180
  • Alkermes, Inc.$145
  • plus $646 from 12 others

What the payments were for

  • Food & beverage$2,387100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,387 in reported general payments places this provider in the 80th percentile of 3,248 family providers in South Carolina.

See all family providers in South Carolina

Medicare billing

Part B allowed, 2024
$14,010
Medicare patients
21
Services billed
188

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole46$69,150
SpravatoEsketamine Hcl17$40,430
VraylarCariprazine Hcl20$26,253
TrintellixVortioxetine Hydrobromide12$5,479
Buspirone Hcl134$1,494
Duloxetine Hcl95$1,247
Vilazodone Hcl22$1,055
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine35$927
Trazodone Hcl76$842
Aripiprazole50$743
Bupropion XlBupropion Hcl44$703
Hydroxyzine Hcl37$600
Lamotrigine72$587
Venlafaxine Hcl ErVenlafaxine Hcl26$492
Clonazepam66$474

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$267$69,15046 claims
Johnson & JohnsonSpravato$84$40,43017 claims
AbbVieVraylar$395$26,25320 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$53$5,47912 claims
Almatica Pharma LLCSertraline Hcl$180$35442 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,248 family providers in South Carolina.

Other family in Anderson

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →